RedHill Biopharma Ltd.
RDHL
$1.64
-$0.09-5.20%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 0.00% | -25.44% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.00% | -25.44% | |||
| Cost of Revenue | 0.00% | -10.12% | |||
| Gross Profit | 0.00% | -32.88% | |||
| SG&A Expenses | 0.00% | -10.27% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.00% | -8.84% | |||
| Operating Income | 0.00% | -15.03% | |||
| Income Before Tax | 0.00% | 20.21% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 0.00% | 20.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.00% | 20.21% | |||
| EBIT | 0.00% | -15.03% | |||
| EBITDA | 0.00% | -12.06% | |||
| EPS Basic | 0.00% | 42.98% | |||
| Normalized Basic EPS | 0.00% | -4.69% | |||
| EPS Diluted | 0.00% | 42.98% | |||
| Normalized Diluted EPS | 0.00% | -4.69% | |||
| Average Basic Shares Outstanding | 0.00% | 39.93% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||